Generic Name and Formulations:
Acetaminophen 320.5mg, caffeine 30mg, dihydrocodeine bitartrate 16mg; caps.
Indications for TREZIX:
Moderate-to-moderately severe pain.
Individualize. 2 caps every 4 hours as needed. Max 10 caps/24 hours.
Post-op pain management in children who have undergone tonsillectomy and/or adenoidectomy. Significant respiratory depression (in unmonitored settings or without resuscitative equipment). Acute or severe bronchial asthma or hypercapnia. Paralytic ileus.
Risk of respiratory depression and death related to ultra-rapid metabolizers of codeine (esp. children in post-op tonsillectomy and/or adenoidectomy). Risk of hepatotoxicity may result with acetaminophen doses >4g/day or involving more than one acetaminophen-containing product. Discontinue if anaphylaxis or hypersensitivity reactions occur. Hypotension. Volume depletion. Circulatory shock. Abuse potential. Adrenocortical insufficiency (eg, Addison’s disease). Asthma. Coma. COPD or decreased respiratory reserve (eg, emphysema, severe obesity, cor pulmonale, kyphoscoliosis). Seizures. Delirium tremens. Head injury. Increased intracranial pressure. Myxedema or hypothyroidism. Prostatic hypertrophy or urethral stricture. Toxic psychosis. Acute abdomen. Biliary tract disease. Pancreatitis. Drug abusers. Acute alcoholism. Use lowest effective dose for shortest duration. Renal or hepatic impairment. Elderly. Debilitated. Malnourished. Pregnancy (Cat.C). Labor & delivery, nursing mothers: not recommended.
Potentiation with alcohol, other opioids, sedatives, hypnotics, muscle relaxants, general anesthetics, centrally-acting antiemetics, tranquilizers; reduce dose of one or both drugs. Concomitant phenothiazines or drugs that compromise vasomotor tone; caution. Concomitant MAOIs may cause CNS excitation, hypertension. May be antagonized by agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, buprenorphine). Increased hepatotoxicity risk with anticonvulsants (eg, phenytoin, barbiturates, carbamazepine) or isoniazid. May potentiate warfarin. May be potentiated by disulfiram, quinolones (eg, ciprofloxacin). May antagonize phenobarbital, aspirin.
Analgesic + stimulant + opioid.
Lightheadedness, dizziness, drowsiness, headache, fatigue, sedation, sweating, nausea, vomiting, constipation, pruritus, skin reactions, respiratory depression, orthostatic hypotension, cough suppression, confusion, urinary retention, hepatotoxicity, anxiety, excitement, insomnia, irritability, palpitations, tachycardia, tinnitus.
Endocrinology Advisor Articles
- Effect of HbA1c and Perioperative Glucose on Postoperative Mortality
- GLP-1 Agonists Superior to DPP-4 Inhibitors for Reducing HbA1c, Weight in T2D
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome
- Reducing Total Daily Insulin Dose in T2D: 3-Meal vs 6-Meal Diet
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures
- Metformin May Improve Pregnancy Outcomes in Polycystic Ovary Syndrome
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- No Cardiovascular Benefit With Fenofibrate in T2D and Hypertriglyceridemia
- Cardiovascular Function May Improve After Cure of Cushing Syndrome
- Primary Prevention Outcomes With Aspirin in T2D and Heart Failure